Literature DB >> 7609676

Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent.

N H Riordan1, H D Riordan, X Meng, Y Li, J A Jackson.   

Abstract

Ascorbic acid and its salts (AA) are preferentially toxic to tumor cells in vitro and in vivo. Given in high enough doses to maintain plasma concentrations above levels that have been shown to be toxic to tumor cells in vitro, AA has the potential to selectively kill tumor cells in a manner similar to other tumor cytotoxic chemotherapeutic agents. Most studies of AA and cancer to date have not utilized high enough doses of AA to maintain tumor cytotoxic plasma concentrations of AA. Data are presented which demonstrate the ability to sustain plasma levels of AA in humans above levels which are toxic to tumor cells in vitro and suggests the feasibility of using AA as a cytotoxic chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609676     DOI: 10.1016/0306-9877(95)90137-x

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  35 in total

Review 1.  New insights into the physiology and pharmacology of vitamin C.

Authors:  S J Padayatty; M Levine
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

2.  Effects of ascorbic acid and β-carotene on HepG2 human hepatocellular carcinoma cell line.

Authors:  Erkan Yurtcu; Ozlem Darcansoy Iseri; Feride I Sahin
Journal:  Mol Biol Rep       Date:  2010-11-30       Impact factor: 2.316

Review 3.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

4.  Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.

Authors:  Qi Chen; Michael Graham Espey; Murali C Krishna; James B Mitchell; Christopher P Corpe; Garry R Buettner; Emily Shacter; Mark Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

5.  The Xc- inhibitor sulfasalazine improves the anti-cancer effect of pharmacological vitamin C in prostate cancer cells via a glutathione-dependent mechanism.

Authors:  Zijie Zheng; Ganhua Luo; Xinchong Shi; Yali Long; Wanqing Shen; Zhoulei Li; Xiangsong Zhang
Journal:  Cell Oncol (Dordr)       Date:  2019-10-15       Impact factor: 6.730

Review 6.  Unconventional therapies for cancer: 5. Vitamins A, C and E. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

7.  O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Authors:  Joshua D Schoenfeld; Zita A Sibenaller; Kranti A Mapuskar; Brett A Wagner; Kimberly L Cramer-Morales; Muhammad Furqan; Sonia Sandhu; Thomas L Carlisle; Mark C Smith; Taher Abu Hejleh; Daniel J Berg; Jun Zhang; John Keech; Kalpaj R Parekh; Sudershan Bhatia; Varun Monga; Kellie L Bodeker; Logan Ahmann; Sandy Vollstedt; Heather Brown; Erin P Shanahan Kauffman; Mary E Schall; Ray J Hohl; Gerald H Clamon; Jeremy D Greenlee; Matthew A Howard; Michael K Schultz; Brian J Smith; Dennis P Riley; Frederick E Domann; Joseph J Cullen; Garry R Buettner; John M Buatti; Douglas R Spitz; Bryan G Allen
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

8.  O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Authors:  Joshua D Schoenfeld; Zita A Sibenaller; Kranti A Mapuskar; Brett A Wagner; Kimberly L Cramer-Morales; Muhammad Furqan; Sonia Sandhu; Thomas L Carlisle; Mark C Smith; Taher Abu Hejleh; Daniel J Berg; Jun Zhang; John Keech; Kalpaj R Parekh; Sudershan Bhatia; Varun Monga; Kellie L Bodeker; Logan Ahmann; Sandy Vollstedt; Heather Brown; Erin P Shanahan Kauffman; Mary E Schall; Ray J Hohl; Gerald H Clamon; Jeremy D Greenlee; Matthew A Howard; Michael K Schultz; Brian J Smith; Dennis P Riley; Frederick E Domann; Joseph J Cullen; Garry R Buettner; John M Buatti; Douglas R Spitz; Bryan G Allen
Journal:  Cancer Cell       Date:  2017-03-30       Impact factor: 31.743

Review 9.  Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.

Authors:  Nermi L Parrow; Jonathan A Leshin; Mark Levine
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

10.  Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.

Authors:  Sebastian J Padayatty; Andrew Y Sun; Qi Chen; Michael Graham Espey; Jeanne Drisko; Mark Levine
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.